Welcome to our dedicated page for Savara SEC filings (Ticker: SVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Savara Inc. (SVRA) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases, and its filings offer detailed insight into the development and financing of its lead program, MOLBREEVI, for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).
Through this page, readers can review current and historical reports such as Forms 8-K, which describe material events including public offerings of common stock and pre-funded warrants, royalty funding agreements tied to potential future U.S. net sales of MOLBREEVI, and updates to corporate presentations. Filings also confirm that Savara’s common stock trades on The Nasdaq Global Select Market under the symbol SVRA and describe the company’s status as a clinical stage biopharmaceutical company focused on rare respiratory diseases.
Key documents for investors include periodic reports like annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain information on research and development expenses, general and administrative costs, and other financial data related to the MOLBREEVI program and corporate operations. Current reports on Form 8-K highlight transactions such as underwritten public offerings, the entry into material definitive agreements, and royalty funding arrangements.
Stock Titan enhances these filings with AI-powered summaries that help explain the significance of complex disclosures, including capital-raising transactions, royalty structures, and covenants described in agreements. Users can quickly understand how specific filings relate to Savara’s rare respiratory disease focus, its Phase 3 development of MOLBREEVI, and its preparation for potential commercialization, while still having direct access to the full text of each SEC document.
Savara Inc. (SVRA) director reports stock option exercise. A Savara director filed a Form 4 reporting the exercise of a stock option for 5,860 shares of common stock on 11/14/2025 at an exercise price of $1.46 per share. After this transaction, the director directly holds 121,326 shares of Savara common stock. The related stock option, which vested in twelve equal quarterly installments beginning on March 15, 2016, has now been fully exercised, leaving 0 derivative securities beneficially owned.
Savara Inc. (SVRA) launched a primary offering of 23,809,524 shares of common stock and pre-funded warrants to purchase 7,142,857 shares. The shares are priced at $4.20 and the pre-funded warrants at $4.199 with a $0.001 exercise price. Gross proceeds are $129,992,857, with underwriting discounts of $7,800,000, for net proceeds before expenses of $122,192,857. The company estimates net proceeds of about $121.7 million after expenses.
The underwriters have a 30‑day option to buy up to 4,642,857 additional shares; if fully exercised, net proceeds before expenses would be $140,522,857. Savara plans to use the funds for working capital and general corporate purposes, including advancing MOLBREEVI toward regulatory approval, building commercialization infrastructure and supply, and launch preparation in the U.S. and EU.
The company also disclosed a purchase and sale agreement with RTW Investments under which Savara would receive $75.0 million upon FDA approval of MOLBREEVI on or before March 31, 2027, in exchange for tiered royalties on U.S. net sales, capped at $187.5 million.
Savara Inc. announced an underwritten offering, agreeing to issue and sell 23,809,524 shares of common stock at $4.20 per share and pre-funded warrants to purchase 7,142,857 shares with a $0.001 exercise price, priced at $4.199 per warrant. The company also granted the underwriters a 30‑day option to purchase up to an additional 4,642,857 shares at the public offering price, less underwriting discounts and commissions.
The transaction was conducted under Savara’s effective Form S-3 shelf, with closing expected on October 31, 2025, subject to customary conditions. Jefferies LLC and Piper Sandler & Co. acted as representatives of the several underwriters. Legal opinions related to the issuance were provided by Polsinelli PC.
Savara Inc. (SVRA) launched a primary offering of common stock and pre-funded warrants under a preliminary prospectus supplement. The company may sell common shares and, for certain existing large investors, pre-funded warrants with a $0.001 per-share exercise price. SVRA’s stock last closed at $4.41 on Nasdaq. The underwriters have a 30‑day option to purchase additional shares. Proceeds are intended for working capital and general corporate purposes, including MOLBREEVI clinical, regulatory, manufacturing, and U.S./EU launch preparations.
As context, shares outstanding were 172,836,922 as of June 30, 2025; this is a baseline figure, not the amount being offered. Pre-funded warrants are exercisable at any time, include 9.99% (up to 19.99% with notice) ownership limits, and will not be listed.
Recent development: SVRA entered a purchase and sale agreement with funds managed by RTW Investments, LP for $75.0 million payable upon FDA approval of MOLBREEVI on or before March 31, 2027, in exchange for tiered U.S. sales royalties ranging from 7.0% to 1.0% (with a 9.5% tier if a prior-year threshold is not met) until the Purchaser receives $187.5 million. A portion of the payment must repay outstanding indebtedness, and the agreement includes customary covenants and a lien on specified IP assets at closing.
Savara Inc. (SVRA) entered a royalty financing with RTW Investments. The Purchaser will pay $75 million to Savara upon FDA approval of MOLBREEVI for autoimmune PAP on or before March 31, 2027, subject to customary closing conditions. In return, RTW receives a true sale of assigned interests, including tiered U.S. Net Sales royalties on MOLBREEVI ranging from 7.0% to 1.0%, with the 7.0% tier rising to 9.5% in a calendar year if the prior year’s Net Sales fall below a specified level, until RTW has received up to $187.5 million in total payments.
Royalties begin in the first calendar quarter of U.S. commercial sales. Savara expects the effective royalty rate over the life of the agreement to be in the low single digits. The agreement includes a buy‑back option tied to certain changes of control within two years of receiving the purchase price, and requires using a portion of proceeds to repay outstanding indebtedness unless otherwise agreed. Savara also disclosed a putative securities class action filed on September 8, 2025 related to public statements on MOLBREEVI; the company intends to defend the case.
Savara Inc. (SVRA) Form 4: The company’s Chief Medical Officer reported equity awards on
Separately, the officer received a stock option for 70,000 shares with an exercise price of
Savara Inc (SVRA) reported an insider ownership update as its Chief Medical Officer filed a Form 3. The filing lists 155,000 shares of common stock beneficially owned, noted to include RSUs that vest in full on December 4, 2025 (80,000) and December 12, 2026 (75,000), each representing a right to one share upon vesting.
Derivative holdings include stock options for 110,000 shares at $4.13 expiring December 11, 2033, vesting in sixteen equal quarterly installments from December 4, 2023, and options for 175,000 shares at $3.35 expiring December 12, 2034, vesting in sixteen equal quarterly installments from December 12, 2024.
Savara Inc. filed a current report to share that it has updated its corporate investor presentation. The new presentation is available on the Investor Relations section of Savara’s website and is also included as Exhibit 99.1 to this report.
The company notes that the information in the presentation and in Item 7.01 of this report is being "furnished" rather than "filed," meaning it is not subject to the usual liability provisions of the Exchange Act and will not be incorporated into other SEC filings unless specifically referenced. Savara also explains that it has no duty to update the presentation, though it may do so in the future through its website, additional SEC reports, press releases, or other public disclosures.
Frazier-affiliated investment vehicles disclosed shared voting and dispositive power over specified Savara Inc. (SVRA) common stock positions. Frazier Life Sciences Public Fund, L.P. directly holds 6,745,296 shares (3.9%); Frazier Life Sciences Public Overage Fund, L.P. holds 2,889,469 shares (1.7%); Frazier Life Sciences X, L.P. holds 324,346 shares (0.2%); and Frazier Life Sciences XI, L.P. holds 1,503,190 shares (0.9%). These percentages are calculated using 172,836,922 shares outstanding as reported by the issuer. The filing clarifies that certain investment committees act by majority vote and explicitly corrects prior attributions of beneficial ownership to individual committee members.
Savara Inc. reported widening losses as it advances its sole product candidate, MOLBREEVI, an inhaled GM-CSF for autoimmune pulmonary alveolar proteinosis. Net loss was $30.4 million for the quarter and $57.0 million for the six months, up from $22.2 million and $42.6 million a year earlier, driven by higher research-and-development and commercial-preparation costs.
The company holds $17.4 million in cash and $129.0 million in short-term investments (total ~$146.4 million) and states this is sufficient to fund operations for at least the next 12 months. Savara received an FDA Refusal to File for its BLA but says the RTF raised CMC information requests only, not safety or efficacy; the company plans a December resubmission and will request Priority Review. Savara has a $200 million Hercules term loan facility with an initial $30 million draw, conditional future tranches tied to regulatory and revenue milestones and covenanted cash requirements that could restrict liquidity.
FAQ
What is the current stock price of Savara (SVRA)?
What is the market cap of Savara (SVRA)?
